BSE List Price : ₹

subscription

Category	Times
QIBs	96.24x
HNIs	2.01x
Retail	0.85x
Total : 2.34x

IPO Market Lot(s) Distribution

Application	Lot Size	Shares	Amount
Retail Minimum	2	2,000	₹248,000
Retail Maximum	2	2,000	₹248,000
S-HNI Minimum	3	3,000	₹372,000
S-HNI Maximum	8	8,000	₹992,000
B-HNI Minimum	9	9,000	₹1,116,000

About the Company

Speciality Medicines Limited (SML), established in 2021, operates in the pharmaceutical industry and is involved in the marketing and distribution of finished specialty pharmaceutical products. Its portfolio includes high-value oral and injectable medicines used to treat complex chronic conditions, catering to both domestic and international markets.

The Company acts as a merchant exporter, trader, and wholesaler, procuring pharmaceutical products from well-established Indian manufacturers. With GDP (Good Distribution Practice) certification, SML is committed to maintaining high standards of safety and quality in its supply chain. Leveraging an expanding global network of suppliers and partners, the Company exports its products to multiple countries, offering a broad range of medicines across various therapeutic segments.

Company Financial Report

_{Amount ₹ in Crores}

Period Ended	Revenue	Expense	PAT	Assets
2024	₹27.66	₹23.10	₹2.93	₹22.68
2025	₹58.54	₹49.85	₹8.61	₹39.98
Oct 2025	₹36.93	₹30.80	₹6.06	₹45.57

Company Promoter

Parth B Goyani

Goyani Sumit Babubhai

Know before investing

• • Strengths

  Broad International Footprint: The Company has operations across India as well as various global markets, enabling a well-diversified revenue stream and lowering reliance on any single region.

  Robust Quality Control Framework: Adheres to stringent quality practices backed by ISO 9001:2015 certification and certified third-party manufacturing units, ensuring consistent product quality and on-time delivery.

• • Risks

  Supplier Concentration Risk: The Company depends on external suppliers for sourcing its products. Any interruption in supply, delays, or fluctuations in pricing could negatively impact product availability, cost structures, and overall operations.

  Research & Development Limitation Risk: The Company does not currently have a well-established in-house R&D function. Any delay in developing this capability may hinder product innovation and affect long-term growth opportunities.

Objects of the Issue & Utilisation of proceeds

Setting up of the Research and Development (R&D) Centre.
Product registration in the international markets.
Repayment/ Prepayment, in full or part, of certain borrowings availed by the Company.
To Meet Working Capital Requirements.
General Corporate Purpose.

Company  Address

Speciality Medicines Ltd.
913, One World West, S. No. 396, FP 119,
Village- Vejalpur, Ahmadabad City,
Ahmedabad, Gujarat, India,
Ahmedabad, Gujarat, 380051
Phone: +91 22 4604 5344
Email: investors.grievances@specialitymedicine.com
Website: https://www.specialitymedicine.com/

IPO Registrar

Skyline Financial Services Pvt. Ltd.
Phone: 02228511022
Email: ipo@skylinerta.com
Website: https://www.skylinerta.com/ipo.php

IPO Review

Avoid